

Saskatchewan Immunization Manual Amendments 2021-09-01

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 10 Biological Products

- AstraZeneca COVISHIELD COVID-19 vaccine
 - Vaccine additional/booster dose eligibility populations added:
As of September 7, 2021 the following people are eligible for an additional 'booster dose'
 - Transplant recipients (including solid organ, islet cell, tissue and hematopoietic stem cell transplants).
 - Recipients of stable, active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders
 - Recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab).
 - Long-term care home and personal care home residents
- Moderna COVID-19 vaccine
 - Vaccine additional/booster dose eligibility populations added:
As of September 7, 2021 the following people are eligible for an additional 'booster dose'
 - Transplant recipients (including solid organ, islet cell, tissue and hematopoietic stem cell transplants).
 - Recipients of stable, active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders
 - Recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab).
 - Long-term care home and personal care home residents
 - NACI statement date and link updated.
 - National Advisory Committee on Immunization. (August 27, 2021). *Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age*. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/mrna-adolescents.html?hq_e=el&hq_m=2189551&hq_l=1&hq_v=91d220e044#a6
- Pfizer COVID-19 vaccine
 - Vaccine additional/booster dose eligibility populations added:
As of September 7, 2021 the following people are eligible for an additional 'booster dose'
 - Transplant recipients (including solid organ, islet cell, tissue and hematopoietic stem cell transplants).
 - Recipients of stable, active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders
 - Recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab).
 - Long-term care home and personal care home residents
 - NACI statement date and link updated.
 - National Advisory Committee on Immunization. (August 27, 2021). *Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age*. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/mrna-adolescents.html?hq_e=el&hq_m=2189551&hq_l=1&hq_v=91d220e044#a6